Safety and the vaccines used
The City of Jyväskylä has suspended vaccination with AstraZeneca vaccine on 19 March 2021.
14.4.2021: AstraZeneca vaccine should only be used in people aged 65 and over.
The safety of the vaccines has been ensured in Finland through wide-ranging cooperation with the European Union and the European Medicines Agency. All vaccines used in Finland must be approved for use within the EU area, an approval that requires thorough research on the usefulness and safety of the vaccine.
At the moment, approval has been granted in the EU area to three coronavirus vaccines:
- Pfizer/BioNTech-developed coronavirus vaccine
- Moderna-developed coronavirus vaccine
- AstraZeneca-developed coronavirus vaccine (only to those over 65 years of age)
All vaccines currently used in Finland must be administered in two doses. The interval between the doses is twelve weeks. The schedules of vaccinations are influenced by how vaccines are obtained in Finland and Central Finland. Health care estimates that vaccinations will last until autumn 2021.
Coronavirus vaccines are being developed at an unprecedented rate, and an enormous amount of resources has been allocated to their development around the world.
Coronavirus vaccines are evaluated on the same quality, safety and efficacy criteria as other medicines. The authorities for medicinal products only grant a marketing authorisation to a vaccine that has been scientifically demonstrated to be both effective and safe. Safety is also monitored after the vaccine is in the market.